

# UBAM - US HIGH YIELD SOLUTION

## Quarterly Comment

For Professional Investors in Switzerland or Professional Investors as defined by the relevant laws. The classification of the fund(s) as per the Sustainable Finance Disclosure Regulation (SFDR) is available on [ubp.com](http://ubp.com) or in the latest prospectus.

### Market Comment

- Following a strong end to last year, risk markets began 2021 on a more cautious note with US investment grade credit spreads flat on the month, and European IG spreads 1 bp wider. The shift in sentiment was highlighted by the spike in equity volatility observed through the VIX index towards the end of January that appeared to have been driven by retail investor activity in certain heavily shorted stocks, which triggered broader de-risking.
- That said, markets still managed to end January relatively unscathed given that from a macro perspective, the vaccine rollout was making strong progress in the US and UK in particular and daily Covid-19 cases continued to decline from the winter peak as lockdown measures began to pay off. Such heavy restrictions also impacted the data however, with payroll numbers in the US moving back into contraction for this first time since April, which was unsurprisingly driven by Covid-19 impacted sectors such as hospitality and leisure.
- January also saw the outcome of the Georgia Senate race in which both Republican seats were taken by the Democrats, resulting in a marginal Blue sweep outcome from the US elections. This fuelled hope of another stimulus package being passed by new President Biden, which also allowed for US Treasury yields to rise and the curve to steepen. For example, US 10-year yields rose by 16 bps during January, with the 5s30s curve steepening by a significant 13 bps as renewed fiscal hopes in the US allowed for the reflation trend to continue. Moves herein came despite Fed Chair Powell in the January press conference noting that the market focus on tapering is premature, adding that the likely rise in inflation this year due to either base effects or a post reopening pick-up in demand, is likely to be transient.
- In contrast, German 10yr Bund yields sold off by just 5 bps in January, outperforming US rates after reports suggested that ECB officials had not ruled out the possibility of a further cut in the depo rate which was rhetoric possibly fuelled by recent EUR strength.
- Interest rate markets took centre stage in February as improving economic data, an accelerating vaccine rollout and hopes for further fiscal stimulus led to a sharp repricing of expectations for Fed rate hikes. By the end of the month the market was pricing in three rate hikes from the Fed by end-2023, in comparison to the Fed's own dot plot which shows unchanged rates during the forecast period. As a result, 10-year US yields rose by 34 bps during February alone, whilst the curve, based on 5-year vs 30-year maturities, was largely unchanged.



Q1 2021

- Whilst the reflation theme had previously been impacting the longer end of the curve, this impact moved towards the front end as the month progressed, as investors questioned the planned trajectory of the Fed. Throughout this period, Fed communication remained unchanged and consistent, with various members noting that yields are rising for good reasons such as higher growth and inflation expectations, although they also noted that the economy remains far from the Fed's own goals. European rates were not immune from this spike in yields with 10-year German Bund yields 26 bps higher in February, although the reaction from various ECB Governing council members suggested less comfort with the pace of the move in long end yields.
- Data during the month also allowed for investors to upgrade their growth projections for 2021 as Global PMIs moved further into expansion, whilst the US Labour market continued to recover, with the headline unemployment rate declining to 6.3%. In addition, the US consumer appeared in good health as US retail sales showed a significant beat to the upside at 5% MoM vs 1% consensus expectations. Investment grade credit spreads were relatively resilient despite the tightening in financial conditions through higher rates observed, instead taking comfort from the better growth prospects ahead. For example US IG spreads ended the month 5 bps tighter at 71 bps, whilst European spreads were 4 bps tighter at 88 bps.
- Interest rate markets remained in focus in March given that US 10-year yields rose back to levels last seen prior to the pandemic spreading globally in February 2020. Moves herein were a continuation of the sharp sell-off in rates observed since the beginning of the year, which has been driven by a combination of improving economic data, an accelerating vaccine rollout, as well as further support coming through fiscal stimulus.
- On the fiscal side, the US administration managed to pass through Congress a significant USD 1.9trn fiscal package which is worth over 8% of GDP and crucially includes stimulus checks which will allow for these funds to be put to use immediately. That said, the rates curve was unable to steepen on this news, given that high frequency data was also impressive in March and kept front end rates under pressure as investors continued to price in the likelihood of the Fed beginning its rate hiking cycle in 2023.
- The manufacturing sector was buoyed by hopes that the vaccine rollout will allow economies to begin lifting restrictions in the coming months, with the US ISM Manufacturing Survey increasing to the highest level since early-2018. Employment data was also impressive with the US unemployment rate declining to 6.2% amid a pick-up in employment in sectors most heavily impacted by the pandemic. Whilst US 10y yields rose by 33 bps during March, in contrast German Bund yields declined by 3 bps during the month.
- This divergence was largely put down to a less successful initial vaccine rollout in the Euro Area, which has come at a time when the region is suffering from another wave of Covid-19 cases, which resulted in various lockdown restrictions being extended. Credit spreads were unable to tighten in March, taking a pause following the significant tightening already observed, as well as digesting the move higher in rates which tightened financial conditions.
- As a result we saw US investment grade credit spreads widening by 6 bps during the month, whilst EUR spreads widened by just 2 bps, managing to outperform given a less volatile EUR rates market as well as enhanced ECB support after they announced an acceleration of PEPP purchases at the February meeting.

---

## Performance Review

- QTD, UBAM - US High Yield Solution returned -0.23% net of fees (I Share class).
- In terms of gross performance contribution QTD, credit contributed +1.10%. Interest rates contributed -1.24%.

---

## Portfolio Activity

- At the end of the quarter, the yield of the portfolio in USD was 5.6%
- The interest rate exposure was 3.5 years.
- The overall credit allocation was:
  - ▶ High yield exposure: 104%
  - ▶ US exposure: 101%
  - ▶ European exposure: 3%
- In January, we took profit on our long iTraxx Crossover position, short duration position and US curve steepening position that we carried over from December as the momentum behind reflation trades appeared to fade post President Biden's inauguration, and due to renewed fears related to the new virus strains combined with a slower vaccine rollout in Europe, which increased uncertainty around economic reopening plans.
- In February, we added reflationary overlay positions to the portfolio. In particular we entered into US interest rate curve steepening positions and short duration positions on the back of the commencement of US fiscal negotiations where we saw indications of a possible larger package than initially anticipated. In addition, US Covid case growth was declining quickly and vaccination progress accelerating, increasing our confidence in the growth rebound.
- In March we increased to credit exposure from 100% to 104% while maintaining the fund's short duration bias given the impressive high frequency data that was released out of the US in particular, including the ISM Manufacturing survey as well as payrolls. This increased our confidence in the growth recovery, which we anticipate will accelerate further once economies begin to re-open in Q2 and should allow for interest rate markets to continue to normalise. We also decided to close the fund's US rates curve steepening position in March. Although we still see room for long-end rates to rise and underperform, in the near term we think that the strength of domestic US data could lead to investors pricing in a more hawkish Fed given their outcome based guidance, which would weigh on the front-end.





---

## Outlook

- Risk markets in Q1 continued on the strong tone that they ended 2020 on, as investors took confidence from the vaccine rollout, which provided hope that some lockdown restrictions would soon be lifted. Growth expectations were also revised higher after US President Biden's fiscal package was passed through Congress, whilst high frequency data released during the quarter was also impressive. For example the March jobs report in the US saw an almost 1mn increase in payrolls, whilst global PMIs rose to a cycle high and led investors to price in more hawkish policy from the Fed in particular over the coming years. Despite this, central banks continued with their dovish tone, emphasising their commitment to maintain accommodation until economies have fully recovered from the pandemic. As we look ahead to Q2, the focus will be on whether vaccine distribution will allow economies to begin reopening, or if any vaccine rollout delays or virus mutations will slow reopening plans. Central banks will also be closely tracked to see if they begin to react to the consistent strength in the data and start guiding towards a less accommodative policy stance down the line.
- US growth outperformed in the first quarter, helped by an accelerating vaccine distribution trend, coupled with support from another fiscal package passed. This latest package was significant, at over 8% of GDP and crucially included stimulus checks which are funds that will be quickly be spent in the real economy, lifting already elevated retail sales growth. Despite this progress, the Fed remained consistent with its messaging and left its dot plot to show unchanged rates throughout the forecast period compared to the market, which is now pricing in around three rate hikes by the end of 2023. One of the main reasons for why the Fed has not followed the market's tightening expectations is due to a change in its reaction function. For example the Fed's maximum employment aim is now a broad based and inclusive goal which we see as an inherently dovish message where they will look to ensure that all minority groups are able to benefit from this recovery, which will likely require an overshoot of aggregate employment targets. Fed Chair Powell himself has repeatedly spoken of the true unemployment rate being closer to 10% right now compared to the official 6% level, as he also takes into account the decline in labour force participation since the commencement of the pandemic. The Fed's new average inflation targeting framework also suggests a more patient approach to tightening as they will now be comfortable seeing inflation above 2% for an extended period of time, given that it has been below 2% for so long. This is a major divergence to what was observed under the previous leadership, where former Chair Yellen looked to tighten policy on the first signs of inflationary pressures building.



- The ECB went a step further than the Fed in Q1 and actually enhanced its dovish support for markets where given lower inflation, less fiscal support and a slower vaccine rollout compared to the US, the Governing Council acted more aggressively against tightening financial conditions. As a result, they announced an increase in the pace of QE purchases through their PEPP programme for Q2 in a bid to manage long end yields. From a fiscal perspective, we see the recent appointment of Mario Draghi as the Italian Prime Minister as a major step in ensuring that EU Recovery Funds are put to good use, which should support peripheral growth in the coming years. Meanwhile there has been some disappointment in relation to near-term growth prospects in the region given a slow initial vaccine rollout and as several countries suffer from a third wave of Covid-19 cases which has led to an extension of lockdowns. However, recent data suggests to us that vaccine distribution is picking up pace and getting back on track, which provides hope for an improving growth trajectory for the region in the coming months.
- From a positioning standpoint, we have been bearish on duration since Q4 and continue to position for higher yields. Although the Fed has been consistent with its dovish messaging, its forward guidance is outcome rather than calendar based, which provides room for investors to keep pricing in the possibility of rate hikes given the strength in the data, which we anticipate will continue as the economy reopens. Ongoing fiscal stimulus measures, coupled with revisions higher in growth and inflation expectations should also allow for the curve to continue to steepen. Although the ECB has been more active in managing the long end of the curve through accelerated PEPP purchases, we think the Governing Council will eventually allow for an orderly move higher in rates, especially if accompanied by stronger growth. We see growth within the Euro Area region as being close to an inflection point here with much of the pessimism around the slow vaccine rollout and latest Covid-19 wave in the price, where investors may soon be surprised to the upside by the pace of the vaccine distribution which should also allow for Bund yields to rise.
- We see this rise in yields as being driven by good reasons of stronger growth expectations, which should allow for risk markets and credit spreads in particular to continue to digest this move well. We anticipate that global growth this year will not only meet its pre-pandemic GDP trend growth level, but actually rise above it as while economies are set to normalise, the stimulus provided by both governments and central banks is here to stay, keeping policymakers as tailwinds to this recovery. Importantly, we think that once central banks are ready to finally tighten policy, this will have been largely priced in and therefore should come as no surprise for investors, in contrast to what was observed during the 2013 Taper Tantrum episode when markets were caught off guard. For credit markets, we think this strong growth environment is one in which the higher beta segments of the market can outperform and where credit compression can take place. High Yield spreads should benefit as the most severely impacted sectors from the pandemic begin to slowly recover, whilst we also think that Subordinated Financial debt provides an attractive opportunity given strong fundamentals for the banking sector and resilient earnings throughout the pandemic, which should also be supported by our expectations of steeper rate curves.

**This is a marketing document and is intended for informational and/or marketing purposes only. It is confidential and is intended to be used only by the person(s) to whom it was delivered.** It may not be reproduced (in whole or in part) or delivered, given, sent or in any other way made accessible, to any other person without the prior written approval of Union Bancaire Privée, UBP SA or any entity of the UBP Group (UBP). This document reflects the opinion of UBP as of the date of issue. This document is for distribution only to persons who are Professional clients in Switzerland or Professional Clients or an equivalent category of investor as defined by the relevant laws (all such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. It is not intended for distribution, publication, or use, in whole or in part, in any jurisdiction where such distribution, publication, or use would be unlawful, nor is it directed at any person or entity at which it would be unlawful to direct such a document. In particular, this document may not be distributed in the United States of America and/or to US persons (including US citizens residing outside the United States of America). This document has not been produced by UBP's financial analysts and is not to be considered financial research. It is not subject to any guidelines on financial research and independence of financial analysis. Reasonable efforts have been made to ensure that the content of this document is based on information and data obtained from reliable sources. However, UBP has not verified the information from third sources in this document and does not guarantee its accuracy or completeness. UBP makes no representations, provides no warranty and gives no undertaking, express or implied, regarding any of the information, projections or opinions contained herein, nor does it accept any liability whatsoever for any errors, omissions or misstatements. The information contained herein is subject to change without prior notice. UBP gives no undertaking to update this document or to correct any inaccuracies in it which may become apparent. This document may refer to the past performance of investment interests. **Past performance is not a guide to current or future results.** The value of investment interests can fall as well as rise. Any capital invested may be at risk and investors may not get back some or all of their original capital. Any performance data included in this document does not take into account fees, commissions, and expenses charged on issuance and redemption of securities, nor any taxes that may be levied. Changes in exchange rates may cause increases or decreases in investors' returns. All statements other than statements of historical fact in this document are "forward-looking statements". Forward-looking statements do not guarantee future performances. The financial projections included in this document do not constitute forecasts or budgets; they are purely illustrative examples based on a series of current expectations and assumptions which may not eventuate. The actual performance, results, financial condition and prospects of an investment interest may differ materially from those expressed or implied by the forward-looking statements in this document as the projected or targeted returns are inherently subject to significant economic, market and other uncertainties that may adversely affect performance. UBP also disclaims any obligation to update forward-looking statements, as a result of new information, future events or otherwise. The contents of this document should not be construed as any form of advice or recommendation to purchase or sell any security or funds. It does not replace a prospectus or any other legal documents, which can be obtained free of charge from the registered office of the fund(s) mentioned herein or from UBP. The opinions herein do not take into account individual investors' circumstances, objectives, or needs. Each investor must make their own independent decision regarding any securities or financial instruments mentioned herein and should independently determine the merits or suitability of any investment. In addition, the tax treatment of any investment in the fund(s) mentioned herein depends on each individual investor's circumstances. Investors are invited to carefully read the risk warnings and the regulations set out in the prospectus or other legal documents and are advised to seek professional counsel from their financial, legal and tax advisors. The tax treatment of any investment in a fund depends on the investor's individual circumstances and may be subject to change in the future. This document should not be deemed an offer nor a solicitation to buy, subscribe to, or sell any currency, funds, products, or financial instruments, to make any investment, or to participate in any particular trading strategy in any jurisdiction where such an offer or solicitation would not be authorised, or to any person to whom it would be unlawful to make such an offer or solicitation. Telephone calls to the telephone number stated in this presentation may be recorded. UBP will assume that, by calling this number, you consent to this recording.

Pursuant to Regulation (EU) 2019/2088 of the European Parliament and of the Council of 27 November 2019 on sustainability-related disclosures in the financial services sector (the "Disclosures Regulation" or "SFDR"), funds are required to make certain disclosures. Funds falling under the scope of Article 6 of the SFDR are those which have been deemed not to pursue an investment approach that explicitly promotes environmental or social characteristics or has sustainable investment as their objective. Notwithstanding this classification, the Investment Managers may take account of certain sustainability risks as further described in the fund's prospectus. Funds falling under the scope of Articles 8 or 9 of the SFDR are those subject to sustainability risks within the meaning of the SFDR. The sustainability risks and principal adverse impacts as stipulated in the SFDR are described in the prospectus. In addition, unless otherwise specified, all funds apply the UBP Responsible Investment Policy, which is available on <https://www.ubp.com/en/investment-expertise/responsible-investment>.

Any subscriptions not based on the funds' latest prospectuses, KIIDs, annual or semi-annual reports or other relevant legal documents (the "Funds' Legal Documents") shall not be acceptable. The Funds' Legal Documents may be obtained free of charge from Union Bancaire Privée, UBP SA, 96-98 rue du Rhône, P.O. Box 1320, 1211 Geneva 1, Switzerland (UBP), from UBP Asset Management (Europe) S.A., 287-289 route d'Arlon, 1150 Luxembourg, Grand Duchy of Luxembourg, and from Union Bancaire Gestion Institutionnelle (France) SAS, 116 avenue des Champs-Élysées, 75008 Paris, France. The Swiss representative and paying agent of the foreign funds mentioned herein is UBP. The Funds' Legal Documents may be obtained free of charge from UBP, as indicated above.

**This content is being made available in the following countries:**

**Switzerland:** UBP is authorised and regulated in Switzerland by the Swiss Financial Market Supervisory Authority (FINMA). The head office is Union Bancaire Privée, UBP SA, 96-98 rue du Rhône, P.O. Box 1320, 1211 Geneva 1, Switzerland. [ubp@ubp.com](mailto:ubp@ubp.com) | [www.ubp.com](http://www.ubp.com)

**United Kingdom:** UBP is authorised in the United Kingdom by the Prudential Regulation Authority (PRA) and is subject to regulation by the Financial Conduct Authority (FCA) and limited regulation by the PRA.

**France:** Sales and distribution are carried out by Union Bancaire Gestion Institutionnelle (France) SAS, a management company licensed with the French Autorité des Marchés Financiers, - licence n° AMF GP98041 ; 116, av. des Champs Elysées | 75008 Paris, France T +33 1 75 77 80 80 Fax +33 1 44 50 16 19 [www.ubpamfrance.com](http://www.ubpamfrance.com).

**Hong Kong:** UBP Asset Management Asia Limited (CE No.: AOB278) is licensed with the Securities and Futures Commission to carry on Type 1 – Dealing in Securities, Type 4 – Advising on Securities and Type 9 – Asset Management regulated activities. The document is intended only for Institutional or Corporate Professional Investor and not for public distribution. The contents of this document have not been reviewed by the Securities and Futures Commission in Hong Kong. Investment involves risks. Past performance is not indicative of future performance. Investors should refer to the fund prospectus for further details, including the product features and risk factors. The document is intended only for **Institutional Professional Investor** and not for public distribution. The contents of this document and any attachments/links contained in this document are for general information only and are not advice. The information does not take into account your specific investment objectives, financial situation and investment needs and is not designed as a substitute for professional advice. You should seek independent professional advice regarding the suitability of an investment product, taking into account your specific investment objectives, financial situation and investment needs before making an investment. The contents of this document and any attachments/links contained in this document have been prepared in good faith. UBP Asset Management Asia Limited (UBP AM Asia) and all of its affiliates accept no liability for any errors or omissions. Please note that the information may also have become outdated since its publication. UBP AM Asia makes no representation that such information is accurate, reliable or complete. In particular, any information sourced from third parties is not necessarily endorsed by **UBP AM Asia**, and **UBP AM Asia** has not checked the accuracy or completeness of such third party information.

**Singapore:** This document is intended only for accredited investors and institutional investors as defined under the Securities and Futures Act (Cap. 289 of Singapore) ("SFA"). Persons other than accredited investors or institutional investors (as defined in the SFA) are not the intended recipients of this document and must not act upon or rely upon any of the information in this document. The financial products or

services to which this material relates will only be made available to clients who are accredited investors or institutional investors under the SFA. This document has not been registered as a prospectus with the MAS. Accordingly, this document and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of this product may not be circulated or distributed, nor may the product be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to institutional investors under Section 274 or 304 of the Securities and Futures Act (Cap. 289) of Singapore ("SFA"), (ii) to relevant persons pursuant to Section 275(1) or 305(1), or any person pursuant to Section 275(1A) or 305(2) of the SFA, and in accordance with the conditions specified in Section 275 or 305 of the SFA, or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. This advertisement has not been reviewed by the Monetary Authority of Singapore.

**MSCI** : Although Union Bancaire Privée, UBP SA information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness of any data herein. None of the ESG Parties makes any express or implied warranties of any kind, and the ESG Parties hereby expressly disclaim all warranties of merchantability and fitness for a particular purpose, with respect to any data herein. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein. Further, without limiting any of the foregoing, in no event shall any of the ESG Parties have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

---